Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia

Clinical Cardiology

Volumn 28, Issue 9, 2005, Pages 423-428

  Leu, Hsin Bang ^a   Chen, Jaw Wen ^a   Wu, Tao Cheng ^a   Ding, Yu An ^a   Lin, Shing Jong ^a   Charng, Min Ji ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Flow mediated vasodilatation; Hypercholesterolemia; Interferon ; Interleukin 18; Matrix metalloproteinase 9

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GAMMA INTERFERON; GELATINASE B; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 18; NITRATE; PLACEBO;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPEREMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 24344445810     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960280907     Document Type: Article

References (29)

1. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 1999;340:115-126
2. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850
3. Mallat Z, Corbaz A, Scoazec A, Besnard S, Tedgui A: Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001;104:1598-1603
4. Mallat Z, Henry P, Fressonnet R, Alouani S, Beaufils P, Chvatchko Y, Tedgui A: Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002;88:467-469
5. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ: Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30
6. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503
7. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Cambien F, Tiret L: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-1585
8. Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, Nicoletti G, Giugliano D: Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 2002;87:3864-3866
9. Esposito K, Nappo F, Giugliano F, Di Palo C, Paolisso G, Giugliano D: Meal modulation of circulating interleukin-18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr 2003;78:1135-1140
10. Son JW, Koh KK, Ann JY, Shin EK: Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003;88:77-82
11. Koh KK: Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000;47:648-657
12. Luan Z, Chase AJ, Newby AC: Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-775
13. Koh KK, Son JW, Ahn JY, Jeong EM, Choi IS, Shin EK: Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002;22:E19-23
14. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80(5):587-595
15. O'Rourke B, Barbir M, Mitchell AG, Yacoub MH, Banner NR: Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: Results of a randomised double-blind, placebo-controlled study. Int J Cardiol 2004;94:235-240
16. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Creager MA, Deanfield J, Vita J, Vogel R, and the International Brachial Artery Reactivity Task Force: Guidelines for the ultrasound assessment of endothelial-dependent, flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265
17. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM: Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004;94:157-161
18. Huang PH, Leu HB, Chen JW, Cheng CM, Huang CY, Tuan TC, Ding PY, Lin SJ: Usefulness of attenuated heart rate recovery immediately after exercise to predict endothelial dysfunction in patients with suspected coronary artery disease. Am J Cardiol 2004;93:10-13
19. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K: Interleukin-18: A novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998;70:281-312
20. Whitman SC, Ravisankar P, Daugherty A: Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 2002 8;90:E34-38
21. Elhage R, Jawien J, Rudling M: Reduced atherosclerosis in interleukin-18-deficient apolipoprotein E-knockout mice. Cardiovasc Res 2003;59:234-240
22. Mallat Z, Corbaz A, Scoazec A: Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001;89:E41-45
23. Mach F: Statins as novel immunomodulators: From cell to potential clinical benefit. Thromb Haemost 2003;90:607-610
24. Chung HK, Lee IK, Kang H, Suh JM, Ro HK, Shong M: Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 2002;34:451-461
25. Tziakas DN, Chalikias GK, Parissis JT, Karas SM, Chatseras DI: Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes: The effects of short-term atorvastatin administration. Int J Cardiol 2004;94:269-277
26. Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. J Am Med Assoc 2001;286:64-70
27. Beckman JA, Liao JK, Hurley S, Garrett LA, Chui D, Mitra D, Creager MA: Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004;95:217-223
28. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A: Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104:376-379
29. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C, and the ACCESS Study Group: Atorvastatin Comparative Cholesterol Efficacy and Safety Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5-hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001;88(3):265-269 429-432